Citimed

Quick links to important sections

Citimed

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Citimed

Quick Facts

Property Description
Active ingredient Citicoline (INN)
Form Tablet, Solution (Injection)
Pharmacological class Nootropic / Neuroprotectant
Common use Supporting memory and cognitive function
Origin Synthetic (derived from a natural compound)

What Type of Medicine is Citimed (Citicoline)?

Citimed contains the single active ingredient Citicoline, which is classified as a neuroprotective and nootropic agent. Citicoline is chemically identical to CDP-choline, a compound naturally found within the body that plays an essential role in the creation and repair of all cell membranes.

The medicine is a synthetic product functionally related to the essential nutrient choline. Its high-level classification falls under the World Health Organization's code N06BX06, grouped among other psychostimulants and neuroprotective agents. Clinical studies have repeatedly supported Citicoline's use in contexts such as helping older adults with age-related memory impairment.


Forms and Composition: How is Citimed Packaged?

Citicoline is typically available as both solid tablets (for oral use) and as a sterile liquid solution for injection. This availability in multiple dosage forms allows the product to be administered orally or parenterally (via injection), providing flexibility depending on patient needs.

As a single-ingredient drug entity, the core composition consists only of the active ingredient, Citicoline (often as its sodium salt), combined with a basic pharmaceutical vehicle. This formulation is designed to ensure maximum bioavailability of the compound to the central nervous system.


What is Citimed’s General Purpose?

The general purpose of Citimed is to provide vital structural support for nerve and brain cells, helping to maintain their integrity. Citicoline works by supplying the necessary chemical building blocks required to stabilize and repair the protective outer layer (the cell membrane) of nerve cells.

This mechanism of delivering structural support and protecting the cell wall is often used to promote optimal functional health in the nervous system. Reviews confirm that Citicoline is an evidenced agent with documented neuroprotective properties investigated for its beneficial effects on cognitive functions. The principle is to help preserve cell structure, which is essential for clear mental function and communication across the nerve network.

What side effects are possible with Citimed?

The safety characteristics and documented adverse reactions of Citimed (Citicoline) are based on formal classifications found in official government regulatory documents.

Frequency and System Classification

Adverse reactions reported in official labeling are primarily classified as Very Rare (less than 1 in 10,000 patients, including isolated reports), reflecting a low overall incidence rate for documented side effects.

System Organ Class Documented Examples
Nervous System Dizziness, headache, fatigue, tremor
Gastrointestinal Diarrhea, stomach pain, nausea, vomiting, epigastric distress
Cardiac/Vascular Bradycardia, tachycardia, arterial hypotension or hypertension
Skin Rash, redness, urticaria

Safety Restrictions and Special Populations

Official regulatory documents define specific safety restrictions and population considerations.

Contraindications list conditions under which the medicine must not be used: these include hypersensitivity to any component and the presence of hypertonia of the parasympathetic nervous system.

The medicine is required to be used with caution in patients with a history of depression, a diagnosis of Parkinson's disease, or trimethylaminuria. Use in children is subject to regulatory constraint, requiring that the expected benefit outweigh any potential risk. While dosage adjustment is not required for older adults, use during pregnancy and lactation is limited to situations where the expected benefit justifies the potential risk.

High-level safety notes include that Citicoline enhances the effects of levodopa, and it should not be used synchronously with medicinal products containing meclofenoxate.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Citicoline (Citimed) consistently indicates that the substance possesses a very low toxicity profile in humans, meaning the occurrence of a severe or specific overdose syndrome is highly unlikely, even if therapeutic doses are accidentally exceeded.

Documented Manifestations and Management

Classification Official Regulatory Statement
Documented Symptoms No specific syndrome is formally documented; high doses may be associated with mild and transient effects such as headaches.
Serious Outcomes No specific life-threatening complications are documented. A precaution notes that large doses could potentially aggravate an increase in cerebral blood flow in cases of persistent intracranial hemorrhage.
Antidote Status No specific antidote for Citicoline overdose is documented or required.

Required Emergency Actions

The official required management for accidental overdose is symptomatic therapy. This means medical professionals are directed to treat any signs or adverse reactions the patient exhibits.

Immediate medical attention is required for any overdose situation involving general life-threatening symptoms. If someone has taken an overdose and is experiencing serious symptoms, such as passing out or trouble breathing, emergency services must be called immediately. For all other suspected overdoses, a poison control center should be contacted right away. Official labeling does not define specific overdose considerations for unique patient populations.

Therapeutic Uses of Citimed

What Citimed Treats: Main Uses and Benefits

Citimed is generally used to help manage symptomatic relief across neurological and cognitive domains. Its clinical applications are relevant across areas where additional symptomatic support is needed.

The substance is applied in clinical settings that involve acute or unstable symptom patterns, such as supportive care following stroke or traumatic brain injury (TBI). It is also commonly used to help with symptom clusters that may become intense or disruptive, including impaired memory function, reduced attention span, and slowed mental processing time associated with age-related cognitive decline. Furthermore, it is considered relevant for easing symptoms in chronic conditions like glaucoma and certain neurodegenerative diseases like Parkinson's.

The therapeutic benefit provided by this substance plays a role in managing symptoms that create noticeable functional strain and can assist with maintaining functional stability. It is applied in scenarios where additional management of discomfort is required, offering supportive relief when symptoms interfere with routine activities.

Quick Fact

Property Description
Relief for Impaired memory, slow processing, functional deficits
Therapeutic Context Post-stroke recovery, Age-related cognitive decline
General Benefit Supports maintenance of functional stability

Eligibility and Restrictions for Use

Who Can and Cannot Use Citimed? (Official Regulatory Information)

Eligibility for Citimed (Citicoline) is determined by regulatory agencies based on established safety and efficacy profiles in specific patient groups. Use is generally established for adults, including older adults, with no mandatory dose adjustment typically required solely due to age.

Classification Population/Condition Restriction Detail (Official Labeling)
Contraindicated Hypersensitivity Patients with a known allergy to Citicoline or any excipients must not use this medicine.
Contraindicated Hypertonia Use is prohibited in patients with increased tone of the parasympathetic nervous system.
Restricted Pregnancy & Lactation Not recommended; should only be used if the expected therapeutic benefit clearly outweighs potential risk.
Limited Use Children & Adolescents Experience is limited and use is not established due to insufficient data; generally not recommended for consumption.
Caution Required Persistent Intracranial Hemorrhage Requires slow administration for injectable forms; large doses could aggravate the condition.
Caution Required Renal Impairment Dosage adjustment may be required in patients with diminished kidney function.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for the active ingredient, Citicoline, is defined by specific, documented drug-drug patterns found within official government regulatory prescribing information. This profile is structured around one formal co-administration restriction and one pharmacodynamic potentiation effect. No interactions involving food, alcohol, or supplements are formally documented as a regulatory interaction rule.


Formal Restrictions and Prohibited Combinations

Co-administration with Meclofenoxate (also known as Clophenoxate) is formally and strictly prohibited. This combination is classified in regulatory documents as a contraindicated combination due to the documented risk of an adverse interaction. The prescribing label establishes this as a mandatory restriction on simultaneous use.


Pharmacodynamic Interactions

The medicine has a documented pharmacodynamic interaction with L-Dopa (Levodopa). Official prescribing information states that Citicoline potentiates the therapeutic effects of L-Dopa. This enhancement of effect means the clinical outcome of L-Dopa may be intensified when the two substances are administered together.


Metabolic and Timing Constraints

The official regulatory documentation does not define specific interaction patterns related to major metabolic enzymes, such as the Cytochrome P450 system, or drug transporters. Furthermore, no mandatory time separation requirements between doses or interaction-related cautions specific to populations, such as those with hepatic or renal impairment, are documented in the official prescribing information.

Mechanism of Action

How Citimed Works

Citimed functions as an inhibitor, primarily targeting the P38beta Kinase signaling cascade within osteoclasts and local immune cells. This molecular interaction reduces the enzymatic activity of P38beta, leading to a decrease in downstream substrate phosphorylation necessary for the activation of matrix metalloproteinases (MMPs).

The consequence of this upstream inhibition is a reduction in the rate of bone matrix degradation. Furthermore, Citimed modulates intracellular signaling by decreasing the activity of the NF-kappa B pathway. This modulation decreases the transcription factor activity required for the synthesis and release of specific pro-inflammatory cytokines, including IL-6 and TNF-alpha. Citimed demonstrates high selective binding affinity for the P38beta isoform over the closely related P38alpha isoform, conferring specificity to its cellular effects. These intracellular actions result in the modulation of localized physiological processes related to cellular stress and catabolism.

Dosage and Administration Information

How to Use Citimed

This section describes the administration and high-level dosing guidelines for Citimed (Citicoline). Citimed is available for both oral administration, using film-coated tablets or oral solution, and parenteral administration via intravenous (IV) or intramuscular (IM) injection.


Official Administration and Dosing

The standard adult oral dosage range prescribed is generally between 500 mg and 2000 mg per day, with the maximum observed dose in clinical practice being 2000 mg (2 g) daily. This dose is typically administered in a once-daily or divided-dose schedule. For parenteral use, the usual daily range is 500 mg to 1000 mg. The choice of route—oral for maintenance or injection for initial acute management—is determined by the patient’s clinical scenario.

Oral administration is typically not dependent on meal timing, as tablets can be taken with or without food. If administered intravenously, the injection must be performed very slowly over a period of three to five minutes to comply with prescribing guidelines.


Usage Adjustments and Constraints

Prescribing information specifies that dosage adjustments are required for patients with renal impairment. While the medicine is sometimes prescribed for older adults, no universal dose change is mandated unless an underlying condition, such as kidney issues, is present. Due to limited clinical data, the use of Citimed in pediatric populations is limited and requires careful consideration.

Injection forms of Citimed are intended for use exclusively under the supervision of a healthcare professional. The overall duration of use is variable, with courses potentially lasting several weeks or months, depending on the therapeutic plan.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Citimed

Research Evidence for Age-Related Cognitive Decline

Research has evaluated Citimed in older adults who have reported memory concerns or mild changes in thinking ability related to age. The main research design includes Randomized Controlled Trials (RCTs). Researchers in these trials measured outcomes related to specific cognitive functions, such as episodic memory and attentiveness, using standardized psychological tests. Many studies described patterns where differences were measured in test scores between those taking Citimed and those taking placebo. These findings suggest that patterns of short-term change were observed, but the overall evidence quality varies and long-term effects are not fully established.


Research Evidence Following Ischemic Stroke

The role of Citimed in recovery after an ischemic stroke was evaluated in major clinical trials, primarily using the RCT design. These studies monitored outcomes focused on functional independence and neurological deficits. Earlier, smaller studies described patterns of functional recovery when compared to a control group. However, later, large-scale trials reported that no statistically significant difference was observed in primary functional endpoints when measuring outcomes several months after the stroke. The data reported patterns of functional recovery that were similar in both the treated and control cohorts, meaning certainty remains low regarding a consistent, reliable functional outcome.


Research Evidence in Traumatic Brain Injury (TBI)

Citimed was studied for use in patients who experienced Traumatic Brain Injury (TBI). A major trial conducted reported measurements showing that no significant difference was observed in the main functional and cognitive outcomes when comparing patients who received Citimed to those who received placebo at 90 days and 180 days post-injury. The overall recovery rates, as observed in the study, were comparable across the groups.


Evidence Gaps and Areas of Uncertainty

The research base has several documented areas of uncertainty. For conditions like glaucoma, the evidence is generally of low quality and relies on small-scale studies measuring electrophysiological biomarkers rather than definitive functional outcomes. Limited information for long-term outcomes is a key gap across nearly all studied conditions, as follow-up durations were limited in many of the key trials. Evidence quality varies across studies, leading to mixed findings that complicate the scientific consensus.

Key Studies & References

  1. Citicoline in the treatment of acute ischemic stroke: a clinical review
  2. Citicoline: a central compound in neurological recovery and brain function
  3. Efficacy of citicoline in patients with acute ischemic stroke: a systematic review and meta-analysis (Representing ICTUS findings)
  4. WHO ATC/DDD Index: N06BX06 Citicoline

Frequently Asked Questions (FAQ)

Common questions about Citimed (FAQ)

Q: What is Citimed actually used for, beyond the official description?

Official regulatory indications state that Citimed is used for conditions relating to cognitive impairment and certain cerebrovascular conditions. Use for any other purpose is considered outside the official scope of the medicine's label. All factual information about the drug's purpose is based strictly on this official documentation.

Q: Does Citimed cause weight gain, according to user experiences?

Based on official regulatory documents, weight gain is not documented or listed as one of the known adverse reactions for Citimed. The reported side effects in official product information mainly focus on gastrointestinal discomfort and effects on the nervous system.

Q: Can Citimed affect sleep patterns, making it hard to fall asleep?

Yes, regulatory documents list insomnia (difficulty falling asleep) as an undesirable effect of Citimed, classified under Psychiatric Disorders. If a patient experiences changes in sleep patterns, this is documented as a possible side effect in official information.

Q: Is Citimed safe to use long-term, for over a year?

Official information indicates that the overall duration of use is determined by the patient’s therapeutic plan. Clinical trials often assess the safety and effectiveness of Citimed over periods of several months, typically ranging up to 6 to 12 months. Regulatory documents emphasize that the continued use of any medication, especially for prolonged periods, requires regular re-evaluation.

Q: Why do people sometimes say Citimed makes them feel 'foggy' or confused?

Official product information documents side effects such as dizziness and headache under Nervous System adverse reactions. While these effects might contribute to a subjective feeling of mental 'fogginess,' the term confusion itself is not explicitly listed among the common adverse effects documented in product information.

Q: If Citimed is used for a nerve issue, does it help repair nerves or just manage symptoms?

The primary mechanism described in official pharmacodynamic information is structural. The active ingredient functions as a precursor chemical that provides necessary components for the repair and stabilization of the outer layers (membranes) of nerve cells. This mechanism focuses on structural support, which is a different function than solely addressing symptoms.

Q: Why is it restricted for people with certain heart conditions?

Citimed requires caution in patients with pre-existing cardiovascular issues because regulatory documents report that it can rarely cause changes in blood pressure or heart rate. Documented adverse reactions include arterial hypotension (low blood pressure), hypertension (high blood pressure), and changes in heart rhythm such as tachycardia or bradycardia.

Q: Is Citimed a 'maintenance' drug, or is it used only short-term?

The duration of use for Citimed is variable. Official prescribing information states that it may be administered for a short course in acute clinical scenarios or for prolonged periods lasting several months in chronic cases. The precise classification of use (e.g., maintenance vs. acute) is based on the therapeutic goals set for the patient.

Q: Can Citimed cause stomach upset, and is there a way to prevent it?

Yes, gastrointestinal discomfort, including symptoms like nausea and stomach pain, is listed as an adverse effect in regulatory documents. Patient information materials often note that taking the medicine with food may help minimize the potential for gastrointestinal adverse effects.

Q: Is there a maximum time a person can safely be on Citimed?

Official labeling does not define a definitive maximum duration for the use of Citimed. Due to limited long-term data, prolonged use, particularly beyond the periods assessed in major clinical trials (often up to 12 months), is typically accompanied by regular monitoring.

Q: Is it true that Citimed can sometimes affect mood or cause anxiety?

Official regulatory documents list the potential for adverse effects such as excitement (classified under Psychiatric disorders) and restlessness. These effects relate to the central nervous system and may correspond to user reports of changes in mood or feelings of anxiety.

Q: Is it better to take Citimed in the morning or at night?

Citimed is prescribed as a once-daily or divided-dose medication. Since insomnia (difficulty sleeping) is listed as a potential side effect, patient information often provides guidance regarding administration time, noting that morning or afternoon dosing may be preferable.

Q: Is there any non-prescription product that is officially mentioned as an interaction?

The official interaction profile is specific and focused on prescription drugs. Regulatory documents state that there are no formal interactions documented with common non-prescription items such as food, alcohol, or dietary supplements. Official documentation does not specifically list non-prescription over-the-counter medicines as prohibited.

Q: Is it necessary to take Citimed at the exact same time every day?

Citimed is typically administered on a once-daily or divided-dose schedule. While maintaining consistent timing helps ensure stable blood levels, regulatory guidance emphasizes adherence to the prescribed frequency and dose, rather than requiring the administration at the exact minute each day.

Q: Are there any known severe allergic reactions associated with Citimed?

Yes, a known allergy or hypersensitivity to the active ingredient is listed as a formal contraindication, meaning the drug must not be used. Documented adverse reactions related to the skin include less severe reactions such as rash and urticaria (hives).

Q: Does Citimed contain gluten, lactose, or any common allergens?

Official prescribing information for some tablet formulations confirms that the excipient lactose is included in the composition. While the presence of gluten is not typically documented, patients with allergies are advised to review the patient information leaflet for the specific formulation being used.

Q: If I miss a dose of Citimed, can I just take it later that day?

Regulatory guidance for a missed dose is to take the dose as soon as it is remembered. However, if it is close to the time of the next scheduled dose, the missed dose is typically skipped entirely. Official information strictly advises against doubling the dose to compensate for a missed one.

Q: Is Citimed available as a generic drug, and is it the same as the brand name?

The active ingredient, Citicoline, is widely available under multiple brand names as well as in a generic equivalent form across many international markets. Generics are generally approved as therapeutically equivalent to the brand name versions, meaning they are expected to have the same effect.

Q: Is Citimed considered addictive or habit-forming?

Citimed is not classified as a controlled substance by regulatory bodies and is not generally considered addictive or habit-forming. Some research has actually examined the ingredient for its potential application in the treatment of certain addictive disorders, supporting its non-addictive profile.

Q: Is Citimed a newer drug, or has it been around for many years?

Citimed is not a newer drug; the active molecule was first developed in Japan in 1956. It has subsequently been used internationally for many decades and is supported by a long history of use for cerebrovascular and cognitive conditions.

Q: Does Citimed stay in your system for a long time after you stop taking it?

Pharmacokinetic data shows that the elimination of the active ingredient's metabolites occurs in two phases. The initial phase has a relatively short half-life of around 3.5 hours, but a secondary, slower phase of elimination can extend the presence of metabolites in the body for up to around 125 hours.

Q: Is it okay to drive or operate machinery while taking Citimed?

Official patient information often notes that due to the potential for central nervous system side effects, such as dizziness and headache, care should be taken when driving or operating heavy machinery.

How should Citimed be stored and disposed of?

How to Store and Dispose of Citimed

The storage and disposal of Citimed (Citicoline) must strictly adhere to the conditions documented in official regulatory labeling.


Storage Requirements

Constraint Official Requirement
Maximum Temperature Store the product below 30 C
Environmental Protection Keep in a dry place and protect from light
Child Safety Keep out of the sight and reach of children
Injectable Solution Single-use only; administer immediately after opening

Disposal Instructions

Expired or unused Citimed should not be disposed of in wastewater or common household trash without taking precautions. The preferred method is to utilize an official drug take-back program or pharmacy collection point. If a take-back program is unavailable, follow regulatory guidance to mix the medicine with an undesirable substance, seal it in a container, and discard it in the household trash. Any unused portion of the injection solution must be discarded immediately.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Citimed found in:

A-Z Index: